Massive study aims to standardize lung cancer testing across labs

NCT ID NCT07624318

Not yet recruiting Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 09, 2026 · Last updated Jun 11, 2026 · Updated 1 time

Summary

This study involves 3,400 people with advanced non-small cell lung cancer to see if a new test for a protein called TROP2 works consistently across different laboratories. The goal is to ensure that doctors can reliably use this test to guide treatment decisions. Participants provide tissue samples, but no new treatments are given.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Research Site

Beijing, Beijing Municipality, 100730, China
Research Site

Guangzhou, Guangdong, 510000, China
Research Site

Shanghai, Shanghai Municipality, 200000, China

Conditions

Explore the condition pages connected to this study.

LUNG CANCER

Conditions inferred from the trial description

These were inferred from the trial's summary, not listed by the trial registrant.

NON SMALL CELL LUNG CANCER